Argenx 1 article

The protein-therapeutics profile of Argenx is anchored in autoimmune antibody therapeutics, with FcRn inhibition adding the receptor, cytokine or multispecific design context that distinguishes its platform. The company links neonatal Fc receptor targeting with pathogenic IgG autoantibody reduction; engineered antibody fragments shows how antibody format or binding architecture is translated into a biological effect. For entity matching, binding format and drug molecule are separate from the organization; Argenx is also associated with myasthenia gravis immunotherapy.